Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Update

Posted by Alphonse Anthony on May 14th, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 245,772 shares, an increase of 284.5% from the April 15th total of 63,926 shares. Currently, 8.0% of the company’s stock are short sold. Based on an average daily trading volume, of 325,146 shares, the short-interest ratio is currently 0.8 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Valion Bio, Inc. Common Stock presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on VBIO

Valion Bio, Inc. Common Stock Stock Down 3.2%

Shares of VBIO stock traded down $0.03 during trading hours on Thursday, hitting $0.94. 39,123 shares of the company were exchanged, compared to its average volume of 236,923. The company has a debt-to-equity ratio of 0.38, a quick ratio of 20.13 and a current ratio of 20.13. Valion Bio, Inc. Common Stock has a one year low of $0.72 and a one year high of $5.60. The business’s 50-day simple moving average is $1.01 and its two-hundred day simple moving average is $1.38. The stock has a market capitalization of $2.94 million, a price-to-earnings ratio of -0.14 and a beta of 1.86.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($408.00) by $406.97.

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.